{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-24-000007","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.528098+00:00","generated_at":"2026-06-05T22:44:21.503574+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Halozyme Q4 revenue $230M (+27% YoY); reiterates 2024 guidance; $750M buyback","bullets":["Q4 revenue $230M (+27% YoY); GAAP EPS $0.65, non-GAAP EPS $0.82; FY23 revenue $829M (+26%).","2024 guidance: revenue $915-985M (10-19% growth), non-GAAP EPS $3.55-3.90 (28-41% growth).","New $750M share repurchase program announced, reflecting confidence in growth.","Partner milestones: argenx VYVGART Hytrulo FDA priority review for CIDP (PDUFA June 21); $23M milestone.","Roche's Tecentriq SC received EU approval; Takeda's HYQVIA approved for CIDP in US and EU."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-24-000007","json":"https://secwatch.observer/filing/0001159036-24-000007.json","markdown":"https://secwatch.observer/filing/0001159036-24-000007.md","text":"https://secwatch.observer/filing/0001159036-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/halo-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:44:21.503574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"155dd68cb014794ec12526880443f74f66262fa1","claim":"HALOZYME THERAPEUTICS, INC. reported 2024 results: revenue $915-985 Million, EPS $3.55-3.90. Guidance reaffirmed.","evidence_excerpt":"Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2024"},{"label":"Revenue","value":"$915-985 Million"},{"label":"EPS","value":"$3.55-3.90"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"6f9e3e1a3e01f108ce6554d64e6c1c4f0e889dad","claim":"HALOZYME THERAPEUTICS, INC. reported Full Year 2023 results: revenue $829.3 million, EPS $2.10.","evidence_excerpt":"Full Year 2023 Revenue Increased 26% YOY to $829 million; GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.77","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$829.3 million"},{"label":"EPS","value":"$2.10"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b99af6b0cdfc4bdba6bfa680b4aa45bb75e5e1de","claim":"HALOZYME THERAPEUTICS, INC. reported Fourth Quarter 2023 results: revenue $230.0 million, EPS $0.65.","evidence_excerpt":"Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.82","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903624000007/0001159036-24-000007-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2023"},{"label":"Revenue","value":"$230.0 million"},{"label":"EPS","value":"$0.65"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}